Introduction: The treatment for patients with high-grade gliomas includes surgical resection of tumor, radiotherapy, and temozolomide chemotherapy. However, some patients do not respond to temozolomide due to a methylation reversal mechanism by the enzyme O-methylguanine-DNA-methyltransferase (MGMT). In patients receiving treatment with temozolomide, this biomarker has been used as a prognostic factor. However, not all patients respond in the same way, which suggests the existence of other proteins involved in resistance to temozolomide chemotherapy.
Methods: A group of thirty-one patients was recruited who were clinically and pathologically diagnosed with high-grade gliomas. The sequencing of 324 genes related to different types of cancer was performed to detect mutations. Subsequently, a statistical analysis was conducted to determine the mutated genes that were most related to resistance to treatment.
Results: According to the Stupp protocol and metronomic dose of the temozolomide treatment, the mutated genes related to the second relapse of patients with high-grade glioma were , , , and .
Conclusions: Considering the results obtained, we suggest that mutations in the four genes and methylation of the gene promoter that codes for the MGMT protein could be related to response to treatment with temozolomide.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3390/biomedicines12122777 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge discovery from database: MRI radiomic features to assess recurrence risk in high-grade meningiomas.
BMC Med Imaging
January 2025
Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Purpose: We used knowledge discovery from radiomics of T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (T1C) for assessing relapse risk in patients with high-grade meningiomas (HGMs).
Methods: 279 features were extracted from each ROI including 9 histogram features, 220 Gy-level co-occurrence matrix features, 20 Gy-level run-length matrix features, 5 auto-regressive model features, 20 wavelets transform features and 5 absolute gradient statistics features. The datasets were randomly divided into two groups, the training set (~ 70%) and the test set (~ 30%).
Biopsy location and tumor-associated macrophages in predicting malignant glioma recurrence using an in-silico model.
NPJ Syst Biol Appl
January 2025
Center for Interdisciplinary Digital Sciences (CIDS), Department Information Services and High-Performance Computing (ZIH), Dresden University of Technology, 01062, Dresden, Germany.
Predicting the biological behavior and time to recurrence (TTR) of high-grade diffuse gliomas (HGG) after maximum safe neurosurgical resection and combined radiation and chemotherapy plays a pivotal role in planning clinical follow-up, selecting potentially necessary second-line treatment and improving the quality of life for patients diagnosed with a malignant brain tumor. The current standard-of-care (SoC) for HGG includes follow-up neuroradiological imaging to detect recurrence as early as possible and relies on several clinical, neuropathological, and radiological prognostic factors, which have limited accuracy in predicting TTR. In this study, using an in-silico analysis, we aim to improve predictive power for TTR by considering the role of (i) prognostically relevant information available through diagnostics used in the current SoC, (ii) advanced image-based information not currently part of the standard diagnostic workup, such as tumor-normal tissue interface (edge) features and quantitative data specific to biopsy positions within the tumor, and (iii) information on tumor-associated macrophages.
View Article and Find Full Text PDFOverall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis.
J Neurooncol
January 2025
Department of Neurosurgery, University Hospital Leipzig, Leipzig University, Liebigstraße, 20, 04103, Leipzig, Germany.
Background: Pediatric meningiomas (PMs) are rare central nervous system tumors, accounting for 1-5% of all meningiomas, and differ from adult meningiomas in clinical, histopathological, and molecular features. Current guidelines primarily focus on adults, leaving a gap in evidence-based management for PMs. This study presents the largest meta-analysis of longitudinal individual patient data (IPD) to date, addressing progression-free survival (PFS) and overall survival (OS) in pediatric patients.
View Article and Find Full Text PDFLu-DOTATATE Plus Capecitabine Versus Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial.
J Nucl Med
January 2025
Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.
View Article and Find Full Text PDFDisseminated enterovirus infection treated with intravenous immunoglobulin in a patient on maintenance ocrelizumab for multiple sclerosis.
BMJ Case Rep
January 2025
Infectious Diseases, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient originally presented with fever, bilateral lower limb swelling and hypoalbuminaemia. She subsequently developed a productive cough and diarrhoea, and a viral respiratory multiplex panel detected rhino/enterovirus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!